Cell Signaling in Drug Discovery — Targeted Therapies Explained

Drug discovery podcast on cell signaling and drug development, with targeted therapies explained in clear scientific detail. Unique deep dive into intracellular signaling proteins, cell communication and disease, and new drug targets 2026 for precision medicine treatments. Understand how drugs work in the body and how personalized medicine and pharmacology are reshaping neuroscience drug development and beyond. What You'll Learn: • Why ~60% of the human proteome is intracellular, yet historically less than 15% has been pharmacologically targeted—and what this untapped space means for future drugs. • How intracellular signaling proteins control disease-relevant pathways and why they’re emerging as prime new drug targets for 2026 and beyond. • The current clinical landscape: what more than 200 ongoing trials involving intracellular signaling modulators reveal about the future of precision medicine treatments. • How kinase inhibitors exploit highly conserved ATP‑binding pockets to achieve nanomolar potency—and why this same feature increases off‑target kinome binding risk. • Practical strategies for improving selectivity profiling to reduce side effects and design safer, more targeted therapies. • How understanding cell communication and disease enables more rational drug design in oncology, immunology, and neuroscience drug development. • Where intracellular targeting fits into the broader shift toward personalized medicine and pharmacology, including potential biomarkers and patient stratification. • Key insights from a new Trends in Pharmacological Sciences review that map out the next generation of targeted therapies. About the Guest: This episode is based on a recent review led by researchers at MedUni Vienna, experts in pharmacology and translational medicine who specialize in decoding intracellular signaling networks. Their work integrates molecular pharmacology, systems biology, and clinical research to identify druggable signaling nodes and design safer, more precise therapies across neurology and other complex diseases. Episode Content: 00:00 – Introduction: Why intracellular signaling proteins are the next big frontier in drug discovery 04:12 – The intracellular proteome: how much is drugged today versus what’s possible 09:25 – How drugs work in the body: from cell signaling to disease pathways 15:48 – Kinase inhibitors, ATP‑binding pockets, and achieving nanomolar potency 22:30 – Off‑target kinome binding and the critical role of selectivity profiling 29:05 – Over 200 clinical trials: the real‑world status of intracellular signaling modulators 36:40 – Precision medicine and personalized pharmacology: matching targets to patients 44:10 – Implications for neuroscience drug development and other therapeutic areas 51:20 – Future directions: new drug targets for 2026 and what to watch next

What You'll Learn:

• Why intracellular proteins represent a huge, still underexploited fraction of the human proteome—and how this opens a new frontier in drug discovery.
• How to interpret the growth of clinical trials involving intracellular signaling modulators and what that means for therapeutic innovation.
• How kinase inhibitors use conserved ATP-binding pockets to reach nanomolar potency, and how to balance this power with the risk of off-target effects.
• Concrete approaches to kinome-wide selectivity profiling to improve safety and efficacy of targeted therapies.
• Ways intracellular signaling modulation can reduce systemic side effects by acting closer to the core of disease-relevant pathways.
• How principles of cell signaling and drug development translate into precision medicine strategies, including biomarker-driven patient selection.
• Why neuroscience and other complex diseases may particularly benefit from intracellular signaling targets and personalized treatment design.
• How insights from the latest Trends in Pharmacological Sciences review can inform your own drug discovery projects or scientific thinking.

About the Guest:

This episode is based on a recent review led by researchers at MedUni Vienna, experts in pharmacology and translational medicine who specialize in decoding intracellular signaling networks. Their work integrates molecular pharmacology, systems biology, and clinical research to identify druggable signaling nodes and design safer, more precise therapies across neurology and other complex diseases.